Delagrèverie, Héloïse M.Delaugerre, ConstanceLewin, Sharon R.Deeks, Steven G.Li, Jonathan2016-11-182016Delagrèverie, Héloïse M., Constance Delaugerre, Sharon R. Lewin, Steven G. Deeks, and Jonathan Z. Li. 2016. “Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents.” Open Forum Infectious Diseases 3 (4): ofw189. doi:10.1093/ofid/ofw189. http://dx.doi.org/10.1093/ofid/ofw189.2328-8957http://nrs.harvard.edu/urn-3:HUL.InstRepos:29408136In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block homeostatic proliferation, and replenish the viral reservoir, eliminate virus-producing cells, and/or control HIV replication after cessation of antiretroviral therapy. This review provides a summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules, and it highlights challenges in the comparison and interpretation of the expected trial results.en-USanti-HIV agentsclinical trialHIV-1latency-reversing agentsviral reservoirJournal Article2016-11-1810.1093/ofid/ofw189